N-[4-[3-[(tert-butylamino)-oxomethyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[[oxo(2-quinolinyl)methyl]amino]butanediamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[4-[3-[(tert-butylamino)-oxomethyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[[oxo(2-quinolinyl)methyl]amino]butanediamide
• 英文别名: N-[4-[3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide
• 化学式: C₃₈H₅₀N₆O₅
• 分子量: 670.8
• InChiKey: QWAXKHKRTORLEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  49
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  167
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• OLIGOMER-PROTEASE INHIBITOR CONJUGATES
  申请人：NEKTAR THERAPEUTICS

  公开号：US20140045770A1

  公开（公告）日：2014-02-13

  The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.

  本发明提供了通过共价结合水溶性寡聚物进行化学修饰的小分子药物。本发明的结合物在通过任何一种给药途径给予时，表现出与未连接水溶性寡聚物的小分子药物不同的特性。
• COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT
  申请人：Nunes, Iseu Da Silva

  公开号：EP2259799B1

  公开（公告）日：2014-03-12
• Combination of Immunomodulator and Anti-Pathogenic Agent
  申请人：Nunes Iseu da Silva

  公开号：US20110028385A1

  公开（公告）日：2011-02-03

  A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance with antimicrobial properties can be administered either jointly, simultaneously, consecutively or sequentially, in an appropriate form, according to their chemical properties, and in a dose effective against microorganisms in human and animals.
• US8889153B2
  申请人：——

  公开号：US8889153B2

  公开（公告）日：2014-11-18
• [EN] MEFLOQUINE, NELFINAVIR AND SAQUINAVIR AS NOVEL AGENTS FOR NEURODEGENERATIVE AND (NEURO-) INFLAMMATORY DISEASES<br/>[FR] MEFLOQUINE, NELFINAVIR ET SAQUINAVIR UTILISES COMME NOUVEAUX AGENTS DANS LES MALADIES NEURODEGENERATIVES ET (NEURO)INFLAMMATOIRES
  申请人：PROTEOSYS AG

  公开号：WO2006108666A1

  公开（公告）日：2006-10-19

  [EN] The present invention generally relates to the neuroprotective, anti-apoptotic and anti-inflammatory activity of mefloquine, nelfinavir and saquinavir and derivatives thereof based on recently discovered interactions with prohibitin and estrogen receptors and the inhibition of mitochondrial voltage- dependent anion channel 1. Thus, mefloquine, nelfinavir and saquinavir and derivatives thereof may be used as medicaments for the prevention and/or treatment of neurodegenerative and inflammatory, particularly neuroinflammatory diseases.
  [FR] L'invention concerne généralement l'activité neuroprotectrice, antiapoptotique et anti-inflammatoire de la mefloquine, du nelfinavir et du saquinavir et de dérivés de ces derniers, basée sur les interactions découvertes récemment avec les récepteurs de la prohibitine et des oestrogènes et sur l'inhibition du canal anionique mitochondrial voltage dépendant 1. On peut par conséquent utiliser la mefloquine, le nelfinavir et le saquinavir et les dérivés de ces derniers comme médicaments dans la prévention et/ou le traitement de maladies neurodégénératives et inflammatoires et, en particulier, de maladies neuroinflammatoires.